These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 19531972)

  • 1. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
    Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
    Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
    Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
    J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
    J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
    Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
    J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
    Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
    Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis.
    Kalnins D; Ellis L; Corey M; Pencharz PB; Stewart C; Tullis E; Durie PR
    J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):256-61. PubMed ID: 16540792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
    J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
    Sander-Struckmeier S; Beckmann K; Janssen-van Solingen G; Pollack P
    Pancreas; 2013 Aug; 42(6):983-9. PubMed ID: 23587850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
    Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
    Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic enzyme replacement therapy for young cystic fibrosis patients.
    Munck A; Duhamel JF; Lamireau T; Le Luyer B; Le Tallec C; Bellon G; Roussey M; Foucaud P; Giniès JL; Houzel A; Marguet C; Guillot M; David V; Kapel N; Dyard F; Henniges F
    J Cyst Fibros; 2009 Jan; 8(1):14-8. PubMed ID: 18718819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
    Delhaye M; Meuris S; Gohimont AC; Buedts K; Cremer M
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):699-703. PubMed ID: 8853261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy.
    Konstan MW; Stern RC; Trout JR; Sherman JM; Eigen H; Wagener JS; Duggan C; Wohl ME; Colin P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1365-71. PubMed ID: 15606399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two pancreatin microsphere preparations in cystic fibrosis.
    Elliott RB; Escobar LC; Lees HR; Akroyd RM; Reilly HC
    N Z Med J; 1992 Mar; 105(930):107-8. PubMed ID: 1553114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Pancrelipase Therapy on Exocrine Pancreatic Insufficiency Symptoms and Coefficient of Fat Absorption Associated With Chronic Pancreatitis.
    Barkin JA; Barkin JS
    Pancreas; 2021 Feb; 50(2):176-182. PubMed ID: 33560089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dependence of PERT endpoint on endogenous lipase activity.
    Gao WY; Mulberg AE
    Pancreas; 2014 Nov; 43(8):1232-8. PubMed ID: 25102439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres--an open randomised crossover preference study.
    Patchell CJ; Desai M; Weller PH; Macdonald A; Smyth RL; Bush A; Gilbody JS; Duff SA
    J Cyst Fibros; 2002 Dec; 1(4):287-91. PubMed ID: 15463829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.